HomeCompareKYSEY vs JNJ

KYSEY vs JNJ: Dividend Comparison 2026

KYSEY yields 2.90% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KYSEY wins by $291.7K in total portfolio value
10 years
KYSEY
KYSEY
● Live price
2.90%
Share price
$11.38
Annual div
$0.33
5Y div CAGR
54.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$321.9K
Annual income
$171,146.98
Full KYSEY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — KYSEY vs JNJ

📍 KYSEY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKYSEYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KYSEY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KYSEY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KYSEY
Annual income on $10K today (after 15% tax)
$246.49/yr
After 10yr DRIP, annual income (after tax)
$145,474.93/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, KYSEY beats the other by $141,488.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KYSEY + JNJ for your $10,000?

KYSEY: 50%JNJ: 50%
100% JNJ50/50100% KYSEY
Portfolio after 10yr
$176.1K
Annual income
$87,918.19/yr
Blended yield
49.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KYSEY
No analyst data
Altman Z
0.8
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KYSEY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKYSEYJNJ
Forward yield2.90%2.13%
Annual dividend / share$0.33$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR54.4%28%
Portfolio after 10y$321.9K$30.3K
Annual income after 10y$171,146.98$4,689.40
Total dividends collected$285.5K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KYSEY vs JNJ ($10,000, DRIP)

YearKYSEY PortfolioKYSEY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,148$447.73$10,592$272.30+$556.00KYSEY
2$12,648$720.23$11,289$357.73+$1.4KKYSEY
3$14,713$1,179.17$12,123$472.89+$2.6KKYSEY
4$17,722$1,979.28$13,141$629.86+$4.6KKYSEY
5$22,403$3,440.22$14,408$846.81+$8.0KKYSEY
6$30,246$6,275.36$16,021$1,151.60+$14.2KKYSEY
7$44,589$12,225.68$18,122$1,588.22+$26.5KKYSEY
8$73,718$26,007.23$20,930$2,228.20+$52.8KKYSEY
9$140,922$62,043.93$24,792$3,191.91+$116.1KKYSEY
10$321,933$171,146.98$30,274$4,689.40+$291.7KKYSEY

KYSEY vs JNJ: Complete Analysis 2026

KYSEYStock

Kyushu Electric Power Company, Incorporated engages in the power generation, transmission, distribution, and sales in Japan and internationally. The company operates through Domestic Electric Power, Other Energy Service, ICT Service, and Other segments. It generates electricity from nuclear, thermal, hydroelectric, geothermal, internal combustion, wind, solar, poultry dung fuel, and biomass power energy sources. The company also receipts, stores, vaporizes, delivers, and sells LNG; purchases, operates, charters, and rents LNG carriers; manufactures and sells electric machinery, specialist equipment, concrete poles, HV and LV insulators, and other products; constructs, maintains, and repairs power generation facilities; buys, leases, manages, cleans, and maintains real estate properties; acquires and owns securities; recycles used confidential documents; and offers geothermal technical and air cargo transportation services, as well as housing and building reviews, assessments and guarantees. In addition, it installs, maintains, and manages electrical measurement equipment; and manufactures, installs, and maintains steel structures. Further, the company offers telecommunication devices, and fiber-optic cable and broadband services; elderly nursing home management and nursing, temporary staffing, and job-placement services; information systems; and computer software. Additionally, it is involved in the heat supply activities; environmental preservation work; consultation, planning, investigation, measurement, design, drafting, and care of civil engineering/construction projects; clerical work acceptance on trust and consulting business; data center business; investment activities; Internet website planning, development, and management; planning and operation of e-sports; management of golf courses; subtitle production for broadcasting; and ownership of mining interests and assets. The company was incorporated in 1951 and is headquartered in Fukuoka City, Japan.

Full KYSEY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this KYSEY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KYSEY vs SCHDKYSEY vs JEPIKYSEY vs OKYSEY vs KOKYSEY vs MAINKYSEY vs ABBVKYSEY vs MRKKYSEY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.